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Abstract
Background: MHC class II transactivator CIITA inhibits the function of HTLV-2 Tax-2 viral transactivator and,
consequently, the replication of the virus in infected cells. Moreover overexpression of the nuclear factor NF-YB,
that cooperates with CIITA for the expression of MHC class II genes, results also in inhibition of Tax-2
transactivation. The purpose of this investigation was to assess the cellular and molecular basis of the CIITA-
mediated inhibition on Tax-2, and the relative role of NF-YB in this phenomenon.
Methods: By co-immunoprecipitation of lysates from 293T cells cotransfected with CIITA or fragments of it, and
Tax-2 it was assessed whether the two factors interact in vivo. A similar approach was used to assess Tax-2-NF-YB
interaction. In parallel, deletion fragments of CIITA were tested for the inhibition of Tax-2-dependent HTLV-2 LTR-
luciferase transactivation. Subcellular localization of CIITA and Tax-2 was investigated by immunofluorescence and
confocal microscopy.
Results: CIITA and Tax-2 interact in vivo through at least two independent regions, at the 1-252 N-term and at the
410-1130 C-term, respectively. Interestingly only the 1-252 N-term region mediates Tax-2 functional inhibition. CIITA
and Tax-2 are localized both in the cytoplasm and in the nucleus, when separately expressed. Instead, when
coexpressed, most of Tax-2 colocalize with CIITA in cytoplasm and around the nuclear membrane. The Tax-2 minor
remaining nuclear portion also co-localizes with CIITA. Interestingly, when CIITA nucleus-cytoplasm shuttling is
blocked by leptomycin B treatment, most of the Tax-2 molecules are also blocked and co-localize with CIITA in the
nucleus, suggesting that CIITA-Tax-2 binding does not preclude Tax-2 entry into the nucleus.
Finally, the nuclear factor NF-YB, also strongly binds to Tax-2. Notably, although endogenous NF-YB does not
inhibit Tax-2-dependent HTLV-2 LTR transactivation, it still binds to Tax-2, and in presence of CIITA, this binding
seems to increase.
Conclusions: These results strongly suggest that CIITA inhibit Tax-2 by binding the viral transactivator both directly or
through a tripartite interaction with NF-YB in. CIITA is therefore a viral restriction factor for HTLV-2 and this open the
possibility to control HTLV-2 viral replication and spreading by the controlled induction of CIITA in infected cells
Background
HTLV-1 (Human T cell Lymphotropic Virus type 1) and
HTLV-2 (Human T cell Lymphotropic virus type 2) are
closely related human retroviruses that belong to delta-
viridae family, subfamily oncovirus type C, characterized
by similar genomic organization and common modes of
transmission but different disease manifestations [1]. It
is estimated that about 15-20 millions of people live
with HTLV infection worldwide [2]. HTLV-1 infection
is endemic in Japan, Africa, South America, and the
Caribbean basin. HTLV-2 infection is highly concen-
trated in Central and West Africa, in native Amerindian
populations in North, Central, and South America, and
among cohorts of intravenous drug users (IVDUs) in* Correspondence: roberto.accolla@yahoo.it
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the United States and Europe [3]. HTLVs are trans-
mitted sexually, by breast feeding or by blood transfu-
sions [4].
HTLV-1 and HTLV-2 show a differential cellular trop-
ism. HTLV-1 has a preferential tropism for CD4+ T
cells [5] while HTLV-2 preferentially infects CD8+ T
cells, although this restriction is not absolute, as both
viruses may also infect B cells, monocytes, microglial
and endothelial cells, at least in vitro [6-8]. HTLV-1 is
the etiologic agent of adult T-cell leukaemia/lymphoma
(ATLL) and of the tropical spastic paraparesis/HTLV-1
associated myelopathy (TSP/HAM) [9-12]. Conversely,
no clear association to specific diseases has been
described for HTLV-2 infection [1].
The basis of HTLV mediated cellular transformation is
not completely understood, but it involves the viral
transactivator protein Tax. Tax is essential for HTLV-1-
and HTLV-2-mediated immortalization of primary
human T cells [13,14] and for tumors induction in
transgenic mice [15,16]. The precise mechanism by
which Tax initiates the malignant process is unclear, but
it seems to involve the de-regulation of several steps
both at transcriptional and post-transcriptional level
[17]. Tax activates transcription of many cellular genes,
including interleukin-2 (IL-2) and IL-2Ra [18,19] and
affects critical signal transduction pathways regulating
cell cycle, cell growth, DNA repair and apoptosis [20].
Many evidences indicate that the transcriptional activa-
tion of cellular genes is mediated by Tax-dependent
activation of transcriptional factors, such as CREB/ATF,
NF-kB and SRF (Serum Responsive Factor). As Tax
plays such an important role in gene expression and
pathogenesis of HTLV viruses, numerous studies have
been directed toward the understanding of the mechan-
ism of Tax transactivation.
We reported that Tax-2 transactivation of the HTLV-
2 LTR is strongly inhibited by the host transcription fac-
tor CIITA. As a consequence, susceptible T and B
human cells do not support HTLV-2 replication when
expressing CIITA [21,22]. Similarly, CIITA targets the
viral transactivator Tat to inhibit the replication of the
HIV-1 virus [23,24].
The AIR-1 locus-encoded class II transactivator CIITA
is the master regulator of the expression of Major Histo-
compatibility Complex class II (MHC-II) genes [25-27].
MHC-II-encoded molecules play a key role in the home-
ostasis of the immune system. They present peptides to
the antigen receptor of CD4+ T cells (TH), whose acti-
vation is required to trigger and modulate both humoral
and cellular immune responses [28]. CIITA is a non-
DNA-binding transcriptional integrator recruited to
MHC-II promoters via multiple interactions with tran-
scription factors bound to DNA, including the RFX and
the NF-Y complexes [29-34]. It interacts with CBP,
p300, PCAF as well as the cyclin T1 subunit of the posi-
tive transcription elongation factor b (P-TEFb) to
enhance MHC-II gene transcription [35-38]. P-TEFb is
also used by Tat to promote the elongation of HIV-1
viral transcripts [39] and we have shown that sequestra-
tion of cyclin T1 is the major mechanism by which
CIITA blocks the transactivating function of Tat [23].
On the contrary, the molecular basis of the CIITA-
mediated inhibition of Tax-2 is still not completely
understood. Previous investigations have established that
the CIITA 1-321 N-terminal region, with an exclusive
nuclear distribution, inhibits Tax-2 function and viral
replication. We identified CBP and p300 as crucial fac-
tors for the Tax-2-directed LTR transactivation. How-
ever, they are not involved in CIITA-mediated
inhibition of Tax-2. Instead the overexpression of the
ubiquitous transcription factor NF-YB, that interacts
with CIITA in the MHC class II enhanceosome, was
found to inhibit Tax-2 transactivating function [21].
In this paper we have investigated the intimate mole-
cular nature of the CIITA mediated inhibition of Tax-2.
We found that both CIITA and NF-Y interact in vivo
with Tax-2. We identified both an N-terminal and a C-
terminal region of CIITA interacting with the viral
transactivator, although, as stated above, only the N-
terminal region is involved in the inhibition of Tax-2
function. Interestingly, in absence of CIITA, endogenous
NF-YB can still bind to Tax-2, although, as we have pre-
viously shown, this interaction does not results in func-
tional inactivation of Tax-2 on the HTLV-2 LTR
promoter. CIITA-NF-YB interaction in vivo is stabilized
and/or favoured by the presence of Tax-2. Thus conco-
mitant interaction of Tax-2 with CIITA and NF-YB,
most likely in the CIITA-NF-YB molecular complex, is
at the basis of the functional inactivation of Tax-2 lead-
ing to the inhibition of HTLV-2 retrovirus replication.
Further studies of subcellular localization unveiled the
co-localization of Tax-2 and CIITA both in the cyto-
plasm and the nucleus, and the role of CIITA in redir-
ecting, upon binding, Tax-2 molecules mostly in the
cytoplasm.
These results are discussed within the present knowl-
edge of cell host-pathogen interaction and the identifica-
tion of the dual role of CIITA as modulator of adaptive
immunity and restriction factor against human
retroviruses.
Methods
Plasmids
Full length CIITA (pcDNA3flagCIITA1-1130) and
deletion mutants of it (pcDNA3flagCIITA1-252,
pcDNA3flagCIITA1-321, pcDNA3flagCIITA253-1130,
pcDNA3flagCIITA253-410) vectors have been described
[40]. The flag tag does not affect protein expression and
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CIITA capacity to transactivate class II promoters. Tax-
2 V5 plasmid was a gift of Prof. Bertazzoni, University
of Verona, Italy. NF-YB cDNA (pcDNA3mycNF-YB)
has been described [33].
Transient transfections, Co-Immunoprecipitation and
Western blotting
Human embryo-derived kidney cell line 293T was main-
tained in DMEM supplemented with 10% FCS and 5
mM glutamine at 37°C and 5% CO2). 293T cells were
transfected with expressing constructs for the full-length
Flag-CIITA or Flag-CIITA deletion fragments using
Lipofectamine (Invitrogen, by Life technology, UK) fol-
lowing the manufactory protocol. After 24 h, cells were
collected, resuspended in lysis buffer (1% NP-40, 10
mM Tris-HCl pH 7.4, 150 mM NaCl, 2 mM EDTA)
supplemented with 0,1% protease inhibitor mixture
(Aprotin, Bestain, E-64, Leupetin, pepstain A, Sigma
Aldrich Italia SRL, Milan, Italy) for 45 min on ice and
centrifuged for 15 min, 14.000 rpm at 4°C. After pre-
clearing the extracts with 10 μl of 100% mouse Protein
A Sepharose 4 fast flow beads (Amersham Pharmacia,
Milan, Italy) for 30 minutes at 4°C by rotation, 0.5 μl of
anti-V5 antibody (Invitrogen) were added and the
mixture incubated for 1 hour on ice and then reacted
with 50 μl of Protein A Sepharose 4 fast flow overnight
at 4°C by rotation. Alternatively cell lysates were immu-
noprecipitated with 50 μl of anti-Flag M2 Affinity Gel
(Santa Cruz Biotechnology, Santa Cruz, CA). An aliquot
corresponding to 12% of the total cell extract was con-
served for proteins expression detection (input). Immu-
nocomplexes were collected by centrifugation, washed
five times with the above lysis buffer and once with the
lysis buffer containing 500 mM NaCl. The immunocom-
plexes were detected after SDS-PAGE and Western blot-
ting as described [23] with either the anti-c-Myc
antibody (9E10 monoclonal antibody, Santa Cruz Bio-
technology, Santa Cruz, CA), the anti-Flag M2 or anti-
CIITA 7-1H monoclonal antibodies (Sigma Aldrich), or
the anti-NFYB polyclonal rabbit antiserum (Santa Cruz),
followed by an HRP-conjugated anti-rabbit or anti-
mouse Ig secondary antibody (Amersham Pharmacia,
Milan, Italy). To detect Tax-2 V5 protein we used the
anti-V5 antibody directly conjugated with HRP (anti-V5-
HRP antibody, Sigma Aldrich). Blots were developed by
chemiluminescence assay (ECL, Amersham Pharmacia).
Immunofluorescence staining
Human 293T cells were seeded on glass coverslips and
transiently transfected with 1.5 μg of the indicated
expression vectors with Lipofectamine (Invitrogen). 24 h
post-tranfection the cells were fixed by incubation with
100% methanol at -20 for 6 min. The cells were washed
with PBS and blocked for 1 h in PBS containing 0.5%
gelatin (Biorad) and 0.5% bovine serum albumine
(Sigma), before overnight incubation at 4°C with
monoclonal V5 antibodies (Invitrogen) diluited 1:750
in the blocking solution. Goat anti-mouse IgG2a Fab
conjugated to Alexa Fluor 546 (Molecular Probes) was
used as secondary antibody. Samples were then
mounted in Fluor Save reagent (Calbiochem) and ana-
lyzed with a laser scanning confocal microscope
(Leica) using a 63 × objective and light source wave-
lengths of 488 and 543 nm.
Results
CIITA interacts with Tax-2 in vivo
In order to verify whether CIITA-mediated inhibition of
Tax-2 could correlate with a direct binding between the
two factors, flag-tagged CIITA and V5-tagged Tax-2
were transiently co-expressed in 293T cells. Cell lysates
were immunoprecipitated with the anti-V5 antibody and
immunocomplexes were examined for the presence of
flagCIITA by anti-Flag western blotting. Results clearly
indicate that CIITA and Tax-2 strongly interact each
other in vivo (Figure 1, top panel, lane 5)
To define the region(s) of CIITA mediating the interac-
tion with the viral transactivator, several truncated forms
of CIITA were tested for their ability to bind Tax-2 by
co-immunoprecipitation assay in 293T cells. When either
CIITA full length or CIITA fragments were expressed in
absence of Tax-2 no specific bands were detected. A non
specific band of 55 kD was present in all immunoprecipi-
tates (Figure 1A, top panel, lanes 1-8).
The N-term fragment fCIITA 1-252 interacted
strongly with Tax-2 (Figure 1, top panel, lane 6). Inter-
estingly, also the complementary C-term fragment 253-
1130 interacted with Tax-2 (Figure 1A, top panel, lane
7). An overlapping N-term fragment fCIITA 253-410,
although well expressed after transfection, (Figure 1A,
lower panel input, lane 8) only slightly interacted with
Tax-2 (Figure 1A, top panel, lane 8) as compared to the
fCIITA 1-252 and fCIITA 253-1130 fragments. These
results indicate a complex pattern of interaction
between CIITA and Tax-2 with at least two regions of
CIITA, encompassing the N-term1-252 and at the C-
term 410-1130 of the molecule, respectively, strongly
interacting with the viral transactivator, although we
cannot exclude that residues included in the 253-410
region, themselves very weakly interacting with Tax2,
may participate in generating the correct conformation
for the critical binding site of the strongly interacting
253-1130 CIITA fragment.
The CIITA N-term 1-252, but not the C-term 253-1130,
region inhibits Tax-2 transactivating activity in 293T cells
It has been previously shown that the N-terminal region
of CIITA mediates the inhibition of Tax-2-
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dependent HTLV-2 LTR transactrivation in COS-7
cells [21,22]. As the interaction studies described here
were performed instead in human 293T cells, and at
least two regions were shown to interact with Tax-2, it
was important to assess the pattern of CIITA-mediated
inhibition of Tax-2 function in these cells, representative
of the species naturally infected by HTLV-2
To this end cells were co-transfected with a fixed
amount of the Tax-2 expression vector (pTax-2 V5) and
increasing amounts of plasmids encoding CIITA wild
type (pfCIITA 1-1130), N-term (pfCIITA 1-252, or
pfCIITA 1-321) or C-term (pf253-1130) fragments,
respectively. It must be noted that in this assay 10 fold
less DNA was transfected into the cells as compared to
the interaction mapping of Figure 1.
Results show that Tax-2-mediated activation of the
viral LTR promoter (Figure 2A, bar 3) was significantly
inhibited by CIITA wild type (Figure 2A, bars 4 and 5)
and the N-term 1-252 and 1-321 CIITA fragments
(Figure 2A, bars 6-7 and 10-11, respectively) in a dose-
dependent manner, whereas the C-term 253-1130
fragment (bars 8-9) exerted only a modest inhibition on
Tax-2 activity. CIITA wt expression vector did not
significantly affect basal promoter activity (Figure 2A,
bar 2; Figure 2B).
Figure 1 CIITA interacts with Tax-2 in vivo. 293T cells were
transiently co-transfected with either one of the following CIITA
plasmids pcfCIITA wt (3 μg), pcfCIITA 1-252 (3 μg), pcfCIITA 253-
1130 (3 μg), pcfCIITA 253-410 (3 μg), pcfCIITA 1-321(1.5 μg) and
pTax-2 V5 (2 μg) vector. Extracts were immunoprecipitated (IP) with
the anti-V5 monoclonal antibody and the purified complexes were
immunoblotted (WB) with the anti-Flag antibody for the detection
of CIITA and its deletion fragments (top panels). The expression of
the proteins in all cell extracts was also examined by WB (input)
with the anti-Flag antibody. TFIIB was used as a control to show
that equal amounts of total protein were loaded in each lane
(bottom panels). To be noted, the input expression of the CIITA
fragment 1-252 was evaluated in a different western blot gel as
underlined by the lines in lane 2. IgH, non specific band
representing the immunoglobulin heavy chain of the anti-V5
antibody recognized in western blots after immunoprecipitation and
detection with HRP-conjugated anti-rabbit or anti-mouse Ig
secondary antibody.
Figure 2 The CIITA N-term 1-252, but not the C-term 253-1130,
region inhibits Tax-2 transactivating activity in 293T cells. A)-
Luciferase gene reporter assay performed in 293T cells transiently
co-transfected with fixed amounts (0.2 μg) of pLTR-II-Luc and pcTax-
2 V5.(0.05 μg) vectors and in the absence or presence of increasing
amounts (0.5-1 μg) of vectors coding for Flag-tagged CIITA wt
(pfCIITA 1-1130) and fragments (pfCIITA 1-252 and pfCIITA 253-
1130). Lower amounts of vector coding for flagCIITA 1-321 fragment
(0.25-0.5 μg) were transfected. The black histogram represents the
LTR-2 promoter activation by Tax-2 (bar 3). Bar 1 represents the
control activity of the pcDNA3 vector alone. B)- CIITA did not affect
basal promoter activity even after transfection of increasing
amounts of CIITA plasmid. The expression of recombinant fCIITA
proteins in all cell extracts were detected by anti-Flag Western blot
(WB) (bottom panel).
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Thus, also in 293T cells CIITA-dependent inhibition
of Tax-2 function correlates with the N-term 1-252
region of CIITA. Furthermore, these results strongly
suggest that interaction between the N-terminal, but not
the C-terminal, part of CIITA, and Tax-2 is responsible
of the biological effect of CIITA on the viral
transactivator.
Tax-2 and NF-YB interact in vivo
Previous results from our laboratory have shown that
the ubiquitously expressed nuclear transcription factor
NF-YB, which interacts and co-operates with CIITA in
activating HLA-II genes transcription, could inhibit the
HTLV-2 LTR promoter transactivation by Tax-2 in
COS-7 cells when over-expressed after transfection [22].
Similar experiments performed in 293T cells resulted in
comparable findings (data not shown).
In order to investigate whether NF-YB could also
interact with Tax-2 in vivo we performed initially co-
immunoprecipation experiments by using lysates of
293T cells co-transfected with myc-tagged NF-YB
(mNFYB) and V5-tagged Tax-2. Results presented in
Figure 3A show that Tax-2 interacts with NF-YB not
only in the presence of co-transfected CIITA (Figure
3A, aV5 IP, aflag WB, lane 2), but also in the absence
of CIITA (Figure 3A, aV5 IP, amyc WB, lane 1).
Experiments were then carried out to assess whether
endogenous NF-YB could interact in vivo with Tax-2.
Although with the limitations of the relatively low
expression of the endogenous NF-YB protein with
respect to the protein expressed after transient transfec-
tion, the interaction of NF-YB with Tax-2 was observed
also in this case (Figure 3B, aV5 IP, aNFYB WB, lane
2). Interestingly, in the presence of co-transfected
CIITA, the amount of co-immunoprecipitated endogen-
ous NF-YB with Tax-2 was clearly increased (Figure 3B,
aV5 IP, aflag WB, lane 3). Taken together, these results
indicate that NF-YB interacts with Tax-2 and this inter-
action can be increased and/or stabilized by the conco-
mitant interaction with CIITA, leading to functional
impairment of Tax-2 function.
Subcellular distribution of Tax-2 in presence of CIITA
In order to obtain a deeper insight into the mechanism
of CIITA-mediated inhibition on Tax-2 function, the
subcellular distribution of Tax-2 molecules was analyzed
in the presence and in the absence of CIITA.
In the absence of CIITA, Tax-2 localizes both and in
the cytoplasm and in the nucleus of 293T cells often
with a punctuated aspect (Figure 4A, panel b). Similarly,
CIITA in the absence of Tax-2, localized in both com-
partments, with a predominant nuclear distribution and
in more diffused aspect as compared to the punctuated
Tax-2 distribution (Figure 4A, panel a).
In the presence of CIITA, Tax-2 is predominantly
accumulated in the cytoplasm and with a marked stain-
ing around the nuclear membrane where it formed a
ring-like structure (Figure 4A, panel d). Interestingly, an
overlapping co-localization of Tax-2 and CIITA was
observed in the cytoplasm as well as in perinuclear ring
(Figure 4A, panel e).
Figure 3 Tax-2 and NF-YB interact in vivo. Panel A- 293T cells
were transiently co-transfected with pcMycNF-YB (2 ug), pcTax-2 V5
(4 ug) and pcfCIITA (3 ug) vectors. Cell extracts were
immunoprecipitated (IP) with the anti-V5 monoclonal antibody and
the purified complexes were immunoblotted (WB) with the indicated
antibodies for the detection of NFYB and CIITA. The expression of the
proteins in whole cell extracts was also examined by WB (input) with
antibodies directed against myc, Flag and V5. Panel B. 293T cells were
transiently transfected with pcTax-2 V5 (4 ug), pcfCIITA (3 ug) and/or
the empty vector pcDNA and immunoprecipitated as in A. The
purified immunocomplexes were immunoblotted with the anti-NFYB
and the anti-Flag antibodies for the detection of the endogenous
NFYB and of CIITA, respectively. The expression of the proteins in
whole cell extracts was also examined by WB (input) with antibodies
directed against NFYB, Flag and V5.
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CIITA contains both nuclear import (NIS) and
nuclear export (NES) signals that allow the molecule to
shuttle between cytoplasm and nucleus. CIITA NES are
CRM-1 dependent, as treatment of CIITA-positive cells
with the CRM-1 inhibitor leptomycin B (LMB) reloca-
lizes CIITA mostly within the nucleus [41,42]. HTLV-2
Tax-2 protein also contain NIS and most likely NES
although the latter have been demonstrated not to be
CRM-1-dependent in HeLa cells [43]. It was therefore
important to assess whether Tax-2 subcellular distribu-
tion in 293T cells could be modified by LMB treatment
in presence or in absence of CIITA. The results pre-
sented in Figure 4B show that LMB treated CIITA-
transfected cells displayed, as expected, an exclusive
CIITA nuclear localization (Figure 4B, panel a). On the
other hand, LMB-treated Tax-2 transfected cells dis-
played a cytoplasmatic and nuclear distribution very
similar to that of untreated cells (Figure 4B, panel b). In
CIITA and Tax-2 co-transfected cells treated with LMB,
again CIITA was exclusively in the nucleus (Figure 4B,
panel c). Interestingly, in this case Tax-2 was also pre-
dominantly localized in the nucleus (Figure 4B panel d)
and a strong nuclear co-localization of the two proteins
was observed (Figure 4B panel e).
Taken together, the above subcellular localization
studies indicate that the physical CIITA-Tax-2 interac-
tion is mirrored by a strong co-localization of the two
molecules in cytoplasmic and nuclear subcellular com-
partments. Moreover and of particular importance,
interaction with CIITA makes Tax-2 molecules prone to
migrate to cytoplasm where they can no longer exert
their transactivating function on the HTLV-2 LTR.
Discussion
Host-pathogen interaction is regulated by a series of
cellular and molecular mechanisms whose outcome dic-
tates in many instances the subtle equilibrium between
control of infection and pathological consequences for
the host. This is particular relevant for pathogens like
human oncogenic retroviruses such as HTLVs whose
infectivity can generate, as clearly demonstrated for
HTLV-1, not only severe infections but also neoplastic
transformation [17]. It is therefore important to investi-
gate possible molecular interactions between host-
derived and virus-derived factors as a necessary frame-
work to understand the evolution of infection. Previous
investigation from our laboratory has demonstrated
that the MHC class II transactivator CIITA could
block the replication of the human HTLV-2 retrovirus
by inhibiting the function of the viral transactivator
protein Tax-2 [21,22]. However the biochemical basis
of the CIITA-mediated inhibition on Tax-2 function
was not clarified. In the present investigation we
focused our analysis on this specific aspect, trying to
understand whether CIITA-mediated inhibition
requires a physical interaction between the cellular
protein and the viral transactivator. Moreover, as the
transcription factor NF-YB, whose interaction with
CIITA is necessary for MHC class II gene transcrip-
tion, was also shown to inhibit Tax-2 when overex-
pressed in COS-7 cells, we investigated whether NF-
YB and Tax-2 physically interacted in vivo.
We demonstrated for the first time the existence of in
vivo interaction between CIITA and Tax-2. (Figure 1)
and shown that this interaction is quite complex as it
involves at least two region of the CIITA molecule
located at the 1-252 N-terminal and mostly at the 410-
1130 C-terminal site. Interestingly, however, and in
similarity to the results obtained in COS-7 cells [22],
only the N-terminal CIITA region was able to function-
ally inhibit Tax-2 dependent HTLV-2 LTR transactiva-
tion in 293T cells. It is of note that the N-terminal
region of CIITA is the one that mostly interacts with
nuclear factors that bind the MHC class II gene promo-
ter region, including general transcription factors regu-
lating initiation of transcription, chromatin modulating
Figure 4 CIITA affects Tax-2 subcellular localization. 293T cells
were transiently transfected with the indicated vectors (GFPCIITA,
Tax2-V5). Eighteen hours post transfection, cells were treated (B) or
not (A) with leptomycin B (20 nm) for 3 hours. Cells were then
washed, fixed, and stained with anti-V5 IgG2a monoclonal antibody
for the detection of V5-tagged Tax proteins (Ab, Ad, Bb, Bd).
GFPCIITA positive cells are shown in Aa, Ac, Ba, Bc. Merged images
are shown in Ae, Be. The images were analyzed by a laser scanning
confocal microscope.
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factors and NF-YB subunit of the NF-Y trimeric com-
plex [34]. It is therefore of particular relevance the find-
ing presented here that also the previously reported
inhibition of Tax-2-mediated LTR transactivation by
overexpression of NF-YB, correlated with a strong bind-
ing in vivo between Tax-2 and NF-YB. In fact, and again
for the first time, we demonstrated in this investigation
that both transfected, thus overexpressed, and endogen-
ous NF-YB could interact with the viral transactivator.
Whether this is a direct interaction or requires a third
partner is presently under scrutiny. Moreover the bind-
ing of endogenous NF-YB with Tax-2 molecules was
increased by the presence of CIITA, strongly suggesting
that at least a trimeric NF-YB-CIITA-Tax-2 complex is
formed in vivo, in the nucleus and this could be a
mechanism preventing Tax-2 from correctly transacti-
vate HTLV-2 LTR and thus viral replication. It remains
to be established whether the binding of the viral trans-
activator with CIITA and NF-YB, prevents Tax-2 from
interacting with its own promoter or the Tax-2 -LTR
promoter complex is formed but is functionally inhib-
ited by a mechanism of steric hindrance.
Although the Tax-2-dependent HTLV-2 LTR transac-
tivation takes place in the nucleus, it is still possible that
additional mechanisms of CIITA-mediated inhibition of
Tax-2 function operate outside the nucleus. For this rea-
son, experiments of subcellular Tax-2 localization in the
presence of CIITA were performed by immunofluores-
cence and confocal microscopy. In the absence of
CIITA, Tax-2 localized both in the cytoplasm and the
nucleus in the great majority of the cells. These results
obtained in 293T cells are only partially similar to those
obtained by other groups, using other cellular systems,
as for example both in HeLa and in HEP-2 cells Tax-2
was mostly localized in the cytoplasm [44,45]. This dis-
crepancy could be due to the biological properties of the
different cell lines analyzed [46]. In the presence of
CIITA, the amount of cytoplasmic Tax-2 was visibly
increased and the viral transactivator strongly co-loca-
lized with CIITA diffusely in the cytoplasm and around
the nuclear membrane in a ring-like fashion. While the
ring-like distribution has been previously observed for
Tax2 colocalizing with calreticulin in a different cell sys-
tem [45], no description of such a localization for
CIITA has been previously reported. Thus, it is likely
that Tax2-CIITA interaction generates either by itself
or, most likely, via the interaction with other proteins
the perinuclear ring-like distribution observed, whose
biochemical and functional meaning remains to be elu-
cidated. Interestingly, although reduced in concentra-
tion, also the nuclear Tax-2 co-localized with CIITA.
Thus, interaction with CIITA makes Tax-2 more prone
to segregate into the cytoplasm. Is this a mechanism to
prevent Tax-2 from migrating into the nucleus and thus
exerting its transactivating function on the HTLV-2 pro-
moter? Two experimental evidences were against this
possibility. First, Tax-2 can bind NF-YB which displays
a predominant, if not exclusive, nuclear distribution
[47]. Second, treatment of the cells with leptomycin B
(LMB) which prevents CRM-1-dependent nuclear export
resulted in a very prominent CIITA and Tax-2 retention
and co-localization in the nucleus. These results strongly
suggest that CIITA-Tax-2 complexes, wherever they
form, shuttle between nucleus and cytoplasm where
they preferentially accumulate, and it is the formation of
the complex, and not the subcellular localization that
makes Tax-2 functionally incompetent in activating the
HTLV-2 LTR promoter. Within this frame the relative
contribution of Tax-2-endogenous NF-YB in vivo inter-
action to the functional impairment of Tax-2 is difficult
to assess, because NF-YB is an ubiquitous factor and
only part of the nuclear Tax-2 molecules are bound by
this factor, as demonstrated by the fact that in presence
of CIITA a proportion of nuclear Tax-2 molecules can
shuttle to the cytoplasm. At the present NF-YB knock-
out cells are not available to study specifically the above
aspect. Future experiments, possibly by using siRNA
technology, will help to clarify this issue.
Conclusions
The direct interaction of CIITA with Tax-2, a crucial
regulator of human oncogenic retrovirus replication,
opens new ways for understanding the peculiar mechan-
isms by which CIITA has evolved its dual function to
counteract pathogens’ infections. From one side, CIITA
triggers the molecular events leading to transcription of
MHC class II genes, whose encoded molecules serve as
antigen presenting receptors for peptides from all sort
of pathogens, including viruses. In so doing CIITA gov-
erns the CD4+ T cell triggering leading to optimal acti-
vation of immune effector mechanisms, particularly
specific antibody production by B cells. Antibody bind-
ing is a crucial event for neutralization of extracellular
viruses which cannot infect host cells and are driven to
degradation. From the other side, the newly acquired
function of CIITA as a molecule that directly binds
HTLV-2 Tax-2, and physically neutralizes its activating
function on viral replication, represents a potent
mechanism of intrinsic immunity. Together with pre-
vious results of our group demonstrating the inhibition
of HIV-1 retrovirus replication by CIITA [23], the
results presented in this study definitively identifies
CIITA as an important viral restriction factor for
human retroviruses. The results of this study may con-
tribute to envisage novel therapeutic strategies aimed at
counteracting retroviral infections through the control
of CIITA expression and/or the selective use of CIITA
fragments.
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